SPCB:NASDAQSuperCom, Ltd. Analysis
Data as of 2026-05-02 - not real-time
$9.74
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
SuperCom Ltd. (SPCB) trades at a forward PE of 9.7, well below the industry average of 31.2, indicating a substantial valuation discount. Technicals are broadly supportive – the 20‑day SMA (8.82) sits above the 50‑day SMA (8.46), the MACD line is bullish, and the RSI at 65 suggests momentum but not yet extreme overbought conditions. Recent news of a national electronic‑monitoring contract in Western Europe and a $17 million win in Sweden point to a resurgence in top‑line growth after a prior ‑10% revenue decline, with Q4 2025 revenues up 18% YoY.
Liquidity remains modest with a market cap of roughly $54 million and average daily volume near 54k, while volatility is high at ~56% and beta exceeds 1.3, flagging elevated market and systematic risk. The stock sits above its $8 support level and below the $10.06 resistance, offering upside potential estimated at ~54% per the analyst consensus.
Liquidity remains modest with a market cap of roughly $54 million and average daily volume near 54k, while volatility is high at ~56% and beta exceeds 1.3, flagging elevated market and systematic risk. The stock sits above its $8 support level and below the $10.06 resistance, offering upside potential estimated at ~54% per the analyst consensus.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technicals showing modest bullish bias but RSI nearing overbought
- Support at $8 and resistance at $10.06 limiting near‑term upside
- Increasing volume confirming recent price moves
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued valuation relative to peers (PE 12.98 vs 31.17 industry)
- Recent contract wins expanding European and U.S. exposure
- Forward PE compression to 9.7 and upside potential >50%
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- High volatility (55% 30‑day) and beta (~1.4) increase systematic risk
- Geopolitical exposure from Israel base and government contracts
- Absence of dividend reduces cash‑return appeal for long‑term holders
Key Metrics & Analysis
Financial Health
Revenue Growth-9.90%
Profit Margin15.53%
P/E Ratio13.0
ROE15.34%
ROA1.12%
Debt/Equity55.31
P/B Ratio1.2
Industry P/E31.2
Technical Analysis
TrendNeutral
RSI65.4
Support$8.00
Resistance$10.06
MA 20$8.82
MA 50$8.46
MA 200$9.43
MACDBullish
VolumeIncreasing
Fear & Greed Index91.09
Valuation
Target Price$15.00
Upside/Downside54.08%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.40
Volatility55.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.